Literature DB >> 30227327

LncRNA THOR increases the stemness of gastric cancer cells via enhancing SOX9 mRNA stability.

Hu Song1, Yixin Xu1, Linseng Shi1, Teng Xu1, Ruizhi Fan1, Meng Cao1, Wei Xu1, Jun Song2.   

Abstract

This work aims to explore the roles and mechanisms of long non coding RNA (lncRNA) THOR in regulating the stemness of gastric cancer cells. RNA-sequencing combined with quantitative real-time PCR (qRT-PCR) indicated that lncRNA THOR level was significantly upregulated in gastric cancer tissues compared with that in normal adjacent tissues. Knockdown of THOR attenuated the stemnness of gastric cancer cells, evident by the decrease of stemness markers expression and capacity of cells spheroid formation. Further RNA-sequencing combined with qRT-PCR and western blot analysis demonstrated that expression of transcriptional factor SOX9 was remarkably decreased in gastric cancer cells with THOR stable knockdown. Additionally, RNA immunoprecipitation (RIP) combined with luciferase reporter assay revealed that THOR directly bound to SOX9 3' untranslated region (3'UTR), but not its 5'UTR or coding area. Notably, overexpression of SOX9 rescued THOR knockdown-mediated inhibition on the stemness of gastric cancer cells. Thus, our results suggest that THOR could potentiate the stemness of gastric cancer cells via directly binding to SOX9 3'UTR.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Gastric cancer; LncRNA; SOX9 3’UTR; Stemness; THOR

Mesh:

Substances:

Year:  2018        PMID: 30227327     DOI: 10.1016/j.biopha.2018.09.057

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  27 in total

Review 1.  Cancer stem cells: a major culprit of intra-tumor heterogeneity.

Authors:  Faiza Naz; Mengran Shi; Salvia Sajid; Zhao Yang; Changyuan Yu
Journal:  Am J Cancer Res       Date:  2021-12-15       Impact factor: 6.166

Review 2.  The regulatory roles and potential prognosis implications of long non-coding RNAs in gastric cancer.

Authors:  Yue Wang; Fan Yang; Qing Yang
Journal:  Histol Histopathol       Date:  2019-12-03       Impact factor: 2.303

Review 3.  Genome-wide methods for investigating long noncoding RNAs.

Authors:  Mei Cao; Jian Zhao; Guoku Hu
Journal:  Biomed Pharmacother       Date:  2018-12-27       Impact factor: 6.529

4.  Long Non-Coding RNA THOR Enhances the Stem Cell-Like Traits of Triple-Negative Breast Cancer Cells Through Activating β-Catenin Signaling.

Authors:  Binbin Wang; Qiang Ye; Chuantao Zou
Journal:  Med Sci Monit       Date:  2020-07-14

5.  LncRNA THOR increases osteosarcoma cell stemness and migration by enhancing SOX9 mRNA stability.

Authors:  Haojun Wu; Yanxia He; Hang Chen; Yanzhi Liu; Bo Wei; Guanghua Chen; Han Lin; Hao Lin
Journal:  FEBS Open Bio       Date:  2019-03-20       Impact factor: 2.693

6.  MIR100HG: a credible prognostic biomarker and an oncogenic lncRNA in gastric cancer.

Authors:  Jun Li; Qingfeng Xu; Wen Wang; Shaojun Sun
Journal:  Biosci Rep       Date:  2019-04-05       Impact factor: 3.840

7.  Long noncoding RNA MALAT1 promotes the stemness of esophageal squamous cell carcinoma by enhancing YAP transcriptional activity.

Authors:  Qi Yao; Jun Yang; Ting Liu; Jianjiang Zhang; Yibo Zheng
Journal:  FEBS Open Bio       Date:  2019-06-11       Impact factor: 2.693

8.  Lnc-THOR silencing inhibits human glioma cell survival by activating MAGEA6-AMPK signaling.

Authors:  Jun Xue; Shan Zhong; Bo-Min Sun; Qing-Fang Sun; Liang-Yun Hu; Si-Jian Pan
Journal:  Cell Death Dis       Date:  2019-11-14       Impact factor: 8.469

9.  A novel N6-methyladenosine (m6A)-dependent fate decision for the lncRNA THOR.

Authors:  Hongmei Liu; Yuxin Xu; Bing Yao; Tingting Sui; Liangxue Lai; Zhanjun Li
Journal:  Cell Death Dis       Date:  2020-08-13       Impact factor: 8.469

10.  lnc-PKD2-2-3, identified by long non-coding RNA expression profiling, is associated with pejorative tumor features and poor prognosis, enhances cancer stemness and may serve as cancer stem-cell marker in cholangiocarcinoma.

Authors:  Gongcai Qiu; Donglai Ma; Fujun Li; Dongsheng Sun; Zhaolin Zeng
Journal:  Int J Oncol       Date:  2019-05-06       Impact factor: 5.650

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.